Clinical Trial Update: Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa [Phase 1]

View source ↗

Summary

Phase 1 trial update showing the efficacy and safety of efalizumab in moderate-to-severe hidradenitis suppurativa, with the study sponsored by NYU Langone Healt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: NYU Langone Health | Conditions: Hidradenitis Suppurativa | Phase 1 | Status: COMPLETED